The activities of aztreonam and cefotaxime against one Escherichia coli strain and three Bacteroides strains have been studied by using pure and mixed cultures of aerobic and anaerobic bacteria. A fixed concentration (8 ,ig/ml) of cefotaxime or aztreonam killed E. coli that was exposed in pure culture, but the pressure of Bacteroides spp. in the same system deteriorated cefotaxime, allowing the full growth of E. coli after 24 h. On the other hand, the presence of Bacteroides spp. produced less deterioration of aztreonam, which reduced the initial E. coli inoculum. This observation could be useful in clinical practice when treating mixed aerobic and anaerobic infections.
Bacteroides spp. in the same system deteriorated cefotaxime, allowing the full growth of E. coli after 24 h. On the other hand, the presence of Bacteroides spp. produced less deterioration of aztreonam, which reduced the initial E. coli inoculum. This observation could be useful in clinical practice when treating mixed aerobic and anaerobic infections.
Aztreonam (SQ 26, 776 ) is a new synthetic antimicrobial agent belonging to the monobactam group of beta-lactams, and its activity is confined mainly to aerobic and facultative gram-negative bacilli, against which it possesses considerable potency, as well as possessing stability to beta-lactamases (2, 3, 5, 8) . The activity of cefotaxime is better known, and it has shown excellent antimicrobial activity in vitro and in vivo against many microorganisms, especially aerobic and facultative gram-negative bacteria (1) . Both aztreonam and cefotaxime have very little activity against Bacteroides fragilis (1, 2, 5, 8) , so their antimicrobial spectra are, in some ways, very similar, although the lower susceptibility of aztreonam to the beta-lactamase produced by this organism (2, 5, 8) could be a major advantage compared with cefotaxime, especially in those clinical infections in which mixtures of aerobic and anaerobic flora are involved.
The aim of the present investigation was to study the in vitro activity of aztreonam and cefotaxime against Escherichia coli and Bacteroides spp. exposed in pure and mixed cultures, such as occur in many clinical infections.
MATERIALS AND METHODS
Bacterial strains. Three clinically isolated Bacteroides strains, two of B. fragilis (strains A and B) and one of Bacteroides vulgatus (strain C), were studied. E. coli ATCC 25922 was also used.
Antimicrobial agents. Cefotaxime and aztreonam were kindly supplied as dry powder with known potency by Hoechst and the Squibb Institute, respectively.
Antimicrobial susceptibility. The MICs of cefotaxime and aztreonam against Bacteroides spp. were determined by the agar dilution method in Wilkins-Chalgren medium (9) with two differenl inocula. In brief, bacteria were grown in enriched brucella broth (6), which was incubated at 37°C in GasPak jars for 24 h. The turbidity of the broth culture was adjusted to match half the density of a McFarland no. 1 standard (ca. 5 x 108 CFU/ml). One dilution of 10-2 was made to prepare two different inocula, which were inoculated with a Steers replicator and then incubated at 37°C in GasPak jars for 24 h. The final inocula were ca. 5 x 105 and 5 x 103 CFU per spot. The MIC was defined as the least concentration of antibiotic that completely inhibited the growth.
The susceptibility of E. coli was determined by the agar * Corresponding author.
dilution method (9) Table 1 shows the MICs of aztreonam and cefotaxime against the three Bacteroides strains, with two different inocula. A very important inoculum effect was that, weight for weight, cefotaxime was more active than aztreonam. The MICs of these two drugs against E. coli were 0.12 ,ug/ml in a state of anaerobiosis. The respective MICs in a state of aerobiosis were 0.12 ,ug/ml for aztreonam and 0.06 ,ug/ml for cefotaxime. Figure 1 shows the data that was obtained in the kinetic studies of the E. coli population that was exposed to a fixed concentration (8 ,ug/ml) of aztreonam or cefotaxime in pure culture and combined with each of the Bacteroides strains. E. coli that was exposed alone to a fixed concentration of cefotaxime was killed very effectively, with an average decrease in inoculum of about 5 (4) showed that in certain experimental circumstances, the early mortality in abdominal sepsis is due to the effect of the facultative bacteria, particularly E. coli, more than to the anaerobic bacterial flora. The use of an antibiotic that is very active against E. coli, such as aztreonam or cefotaxime, may be justified in many clinical infections, especially if no resistant strains, such as Bacteroides strains, are associated with the susceptible ones. In some mixed infections with aerobic and anaerobic bacterial flora, whether they are bacteriologically documented or not, cefotaxime might be useless not only against Bacteroides strains but also against E. coli strains due to the enzymatic degradation of the drug by the Bacteroides strains. It has been shown that some Bacteroides strains reduced in vitro pharmacological levels of cefotaxime, allowing the growth of very susceptible strains of E. coli that were included in the same system (7), This mechanism could 
